N/A N=437 OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
Opioid-use Disorder
Primary: Treatment Success Rate — 70; 67 Participants — p=0.7326
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=49 Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
Opioid-use Disorder
Primary: Proportion of Patients Successfully Inducted to Receive Naltrexone Injection — 12; 7 Participants
Phase 3 N=665 Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine
Opioid Dependence · Opioid Related Disorders
Primary: Cumulative Distribution Function (CDF) of the Percentage of Urine Samples Negative for Opioids Combined With Self-Reports Negative for Illicit Opioid Use Collected From…
Phase 2 N=47 A Multiple Dose Opioid Challenge Study
Moderate or Severe Opioid Use Disorder
Primary: Treatment Phase Drug Liking Visual Analog Scale (VAS) Emax Scores for Baseline and Four Challenge Sessions Compared to Baseline (Completer Population) for CAM2038 q1w…
N/A N=1,731 Opioid Use Disorder in the Emergency Department: CTN 0069
Opioid Use Disorder
Primary: Implementation (Considered the Primary Outcome) — 2; 53 Participants — p=<0.001
Phase 4 N=17 SUBLOCADE Rapid Initiation Extension Study
Opioid Use Disorder, Severe · Opioid Use Disorder, Moderate
Primary: Treatment Emergent Adverse Event (TEAE) Occurrence — 0 Participants
N/A N=321 Subthreshold Opioid Use Disorder Prevention (STOP) Trial
Opioid-use Disorder
Primary: Days of Risky Opioid Use in Past 180 Days — 12.2; 15.5 days
N/A N=119 Stress Response in Opioid Use Disorder
Opioid-use Disorder
Primary: Change in Negative Affect — 1.67; 1.25; 3.60 scores on a scale
N/A N=19 mHealth for Patient Self-Management of Opioid Use Disorder
Opioid-use Disorder
Primary: Usability Score — 89.5 score on a scale
N/A N=104 Start Treatment and Recovery for Opioid Use Disorder
Opioid-use Disorder · Mental Disorder · Opioid Medication Assisted Treatment
Primary: Number of Participants With Self-reported Treatment Retention — 51 Participants
Phase 2 N=39 Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder
Opioid Use Disorder
Primary: Opioid Blockade Following Administration of Hydromorphone Challenge As Measured Using the Subjective Opioid Effects Rating for the Question "Do You Like the Drug?"…
N/A N=29 Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.
Opioid-use Disorder
Primary: Treatment Retention — 5; 5 Participants — p==0.87
Phase 3 N=20 Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders
Substance-Related Disorders · Substance Use Disorders · Substance Abuse, Intravenous
Primary: Opioid Craving Using Visual Analogue Scale — 3.909; 6; 4.556; 5.5 score on a scale
Phase 1 N=27 Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder
Opioid Abuse · Opioid Dependence · Opioid-Related Disorders
Primary: Change in Subjective Response to Oxycodone Measured With 100 Millimeter Visual Analog Scale — -13.81; -9.67 units on a scale
Phase 2 N=30 Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder
Opioid-use Disorder
Primary: The Primary Endpoint Will be Safety and Tolerability of CBD. — 13; 4 participants
Phase 2 N=13 Suvorexant for Opioid/Stimulant Co-use
Opioid Use Disorder · Stimulant Use Disorder
Primary: Opioid Use: Proportion of Positive Urine Drug Screens (UDS) — 0.83; 0.67 Proportion of urine drug screens
Phase 2 N=71 Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections
Drug Use · Opioid-use Disorder
Primary: Illicit Opioid Use — 0.434; 0.360 Proportion of UDS samples
N/A N=1,542 Emergency Department Outcomes for Patients With Opioid Use Disorder
Opioid-use Disorder
Primary: Percent of Participants Who Received Emergency Department (ED)-Initiated/Expedited Buprenorphine (BUP) — 39.40 Percentage of participants
Phase 2 N=51 Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse
Opioid Dependence
Primary: Number of Participants Retained in Study — 18 participants
N/A N=16 Usability Testing for the Reward-based Technology to Improve OUD Treatment
Opioid-use Disorder · Contingency Management · Medication for Opioid-use Disorder
Primary: OARSCM Usability - Phase 1 Usability — 12 Participants
Phase 3 N=227 Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder
Opioid Use Disorder
Primary: Subjects With Treatment-Emergent Adverse Events (TEAE) During the Treatment Period-Overall Safety Population — 131; 12; 58; 2 participants
N/A N=55 Clinical Decision Support for Opioid Use Disorders in Medical Settings: Usability Testing in an EMR
Opioid-use Disorder
Primary: Intervention PCP Confidence in Assessing and Treating OUD — 6; 11; 8; 1 Participants
Phase 2 N=10 An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder
Opioid-use Disorder
Primary: Sublocade Induction — 10 Participants
N/A N=155 Technology for MAT in Primary Care - Phase 2
Opioid-use Disorder
Primary: Urine Drug Screening Test Results — 92.3; 92.0; 1.9; 2.0 percentage of participants positive
N/A N=105 Mindfulness-Based Relapse Prevention to Improve Medication Assisted Treatment Adherence and Drug-use Outcomes for Opioid Use Disorder
Opioid-use Disorder
Primary: Adherence to Medication Assisted Treatment (MAT) — 32; 17 Participants
N/A N=375 Contingency Management to Enhance Office-Based Buprenorphine Treatment
Opioid-use Disorder
Primary: Buprenorphine Adherence as Assessed by the Percentage of Buprenorphine-positive Urine Samples — 80; 84; 78 percentage of urine samples — p==0.22
Phase 2 N=38 Medical Management of Sleep Disturbance During Opioid Tapering
Opioid Dependence · Opioid Withdrawal · Sleep Disturbance
Primary: Abuse Liability as Assessed by Visual Analogue Scale — 23.9; 20.9; 22.8 score on a scale*days — p=.950
Phase 2 N=12 Oxytocin Treatment of Opioid Dependence
Opioid Dependence · Opioid Withdrawal
Primary: Area Under the Curve (AUC) in COWS Total Score on Days 1 to 5 Inclusive — 4.2; 3.4 Average COWS score * hours
Phase 3 N=9 Buprenorphine Treatment for Opioid Dependence
Opioid Dependence
Primary: Urine Toxicology for Opiate Use — 2; 4; 2; 0 Participants
N/A N=200 Psychosocial Pain Management to Improve Opioid Use Disorder Treatment Outcomes
Opioid-use Disorder · Medication Assisted Treatment · Chronic Pain
Primary: Retention on Buprenorphine Treatment According to TimeLine Follow-Back - 3-months — 81.1; 75.4 days